Zoetis Inc
NYSE:ZTS

Watchlist Manager
Zoetis Inc Logo
Zoetis Inc
NYSE:ZTS
Watchlist
Price: 164.7 USD 0.26% Market Closed
Market Cap: 74.3B USD
Have any thoughts about
Zoetis Inc?
Write Note

Zoetis Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zoetis Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Zoetis Inc
NYSE:ZTS
Accrued Liabilities
$1.1B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
18%
Johnson & Johnson
NYSE:JNJ
Accrued Liabilities
$33.5B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Accrued Liabilities
$13.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Accrued Liabilities
$2.6B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Accrued Liabilities
$15.7B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accrued Liabilities
$14.1B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
18%
No Stocks Found

Zoetis Inc
Glance View

Market Cap
74.4B USD
Industry
Pharmaceuticals
Economic Moat
None

In the vast panorama of the global animal health industry, Zoetis Inc. emerges as a formidable player, intricately weaving a narrative of innovation and growth. Originally part of Pfizer, Zoetis embarked on its solo journey in 2013, driven by a singular mission to understand, anticipate, and amplify the needs of both livestock and companion animals. At the heart of its operations lies an impressive pipeline of products—from vaccines and diagnostics to genetic tests and precision livestock farming software—designed to improve the health of animals. Its comprehensive approach ensures not only the well-being of the animals but also supports the burgeoning needs of veterinary practitioners and livestock producers worldwide. Financially, Zoetis masters the art of monetizing its deep-rooted expertise in animal biology and science. Revenue streams flow predominantly from the sale of these innovative products, with livestock and companion animal segments each contributing significant streams of income. The company capitalizes on its extensive global footprint, reaching customers in over 100 countries, ensuring diversified and steady cash flows. Its continued investment in R&D underscores a long-term commitment to innovation, enhancing its product offerings and driving future growth. In a world increasingly conscious of the importance of animal welfare and food security, Zoetis stands at a strategic intersection, aligning its business model with the evolving dynamics of both consumer preferences and regulatory landscapes.

ZTS Intrinsic Value
119.94 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Zoetis Inc's Accrued Liabilities?
Accrued Liabilities
1.1B USD

Based on the financial report for Sep 30, 2024, Zoetis Inc's Accrued Liabilities amounts to 1.1B USD.

What is Zoetis Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
18%

Over the last year, the Accrued Liabilities growth was 8%. The average annual Accrued Liabilities growth rates for Zoetis Inc have been 4% over the past three years , 9% over the past five years , and 18% over the past ten years .

Back to Top